This study looks at how safe and effective a treatment called tabelecleucel is for people with diseases linked to the Epstein-Barr virus (EBV). EBV is a virus that can cause certain diseases. Tabelecleucel is a special type of cell treatment. The study is open-label, meaning all participants know they are getting the treatment. Participants will be grouped based on their specific EBV disease type.

Tabelecleucel is given through a vein (IV) once a week for three weeks in each cycle, which lasts 35 days. The treatment continues until the best possible response is achieved or if the disease worsens. There are safety checks 30 days after the last dose and follow-ups every three months for up to two years.

• The study lasts up to two years, with regular follow-ups.
• Participants are given tabelecleucel IV weekly for three weeks in 35-day cycles.
• Participants must have an EBV-related disease and meet specific health criteria.

Participants must not have certain other diseases or be pregnant. They should also be willing to follow specific medical guidelines during the study.